# 人类生物银行所有权市场

> 人类生物样本库所有权市场研究报告：按应用（研究、临床试验、个性化医学、疾病预防）、按生物样本库类型（公共生物样本库、私人生物样本库、商业生物样本库）、按样本类型（血液样本、组织样本、细胞系、生物液体）、按最终用途（制药公司、学术机构、医疗服务提供者）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 增长前景与行业预测2025至2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.02%
- **2024:** $ 31.94 Billion
- **2025:** $ 33.54 Billion
- **2035:** $ 54.75 Billion
- **Key Players:** Biorepository (US), Global Biobank (GB), Tissue Solutions (GB), Cleveland Clinic Biobank (US), NHS Blood and Transplant (GB), Krebsforschung (DE), BioBanking (FI), Australian Biobank (AU)

**Report ID:** MRFR/HC/35956-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** October 17, 2026

**URL:** https://www.marketresearchfuture.com/reports/human-biobanking-ownership-market-37911

---

## Market Summary

## **Human Biobanking Ownership Market Overview**

As per MRFR analysis, the Human Biobanking Ownership Market Size was estimated at 31.94 (USD Billion) in 2024. The Human Biobanking Ownership Market Industry is expected to grow from 33.54 (USD Billion) in 2025 to 52.13 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.02% during the forecast period (2025 - 2034).

## **Key Human Biobanking Ownership Market Trends Highlighted**

The Human Biobanking Ownership Market is experiencing significant growth driven by the increasing demand for personalized medicine and advancements in genomic research. The rise in chronic diseases and the need for tailored therapies fuel the urgency for comprehensive biobanks that collect and store biological samples. Regulatory support and funding from governments and private entities further bolster this market, enabling more robust biobanking initiatives.

As organizations recognize the value of biobanks in research and development, this demand only intensifies. There are ample opportunities to explore in the realm of collaboration and partnerships. Academic institutions, pharmaceutical companies, and biobanks can forge alliances to enhance research capabilities. Additionally, the growing emphasis on ethical collection methods and consent processes presents a chance to innovate in biobanking practices.

Fostering public trust through transparency in ownership and usage can greatly enhance participation and sample retention, leading to more reliable data for researchers. Recent trends in the market point toward a shift towards decentralized biobanking, where samples are collected in diverse settings rather than centralized facilities. This approach not only increases accessibility but also caters to a wider demographic, ensuring more representative data.

Moreover, advancements in technology, including automation and data management tools, are streamlining biobanking processes, resulting in increased efficiency. The integration of artificial intelligence in analyzing biobank data opens new avenues for discovery and insights, making the market dynamic and ever-evolving. The focus on sustainable practices and ethical considerations continues to shape how biobanks operate, ensuring they adapt to changing societal expectations while maximizing their potential for impactful research.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Human Biobanking Ownership Market Drivers**

### **Increasing Demand for Personalized Medicine**

The trend towards [personalized medicine](../../../reports/personalized-medicine-market-2937) is significantly driving the Human Biobanking Ownership Market Industry. With the rising understanding that individual genetic makeup can influence treatment outcomes, there is a growing requirement for biobanking facilities that store a diverse range of human biological materials. This demand is being fueled by advancements in genomic research, which necessitates a vast repository of human tissues, blood samples, and other biological specimens.

As treatment plans become more tailored to the individual patient based on their unique biological characteristics, the need for comprehensive and ethically managed biobanks expands. This development is further bolstered by research institutions, pharmaceutical companies, and biotech firms focusing on developing targeted therapies. The ability to access a variety of biological samples enables researchers to conduct more accurate studies that can lead to meaningful medical advancements.

As a result, the Human Biobanking Ownership Market is experiencing heightened growth as organizations recognize the necessity of establishing or expanding biobanking capabilities to respond to the progressive shift towards personalized healthcare. Additionally, collaborations between biobanks and research entities are forming to streamline access to biological samples, enhancing research capabilities. As personalized medicine continues to evolve, the significance of the Human Biobanking Ownership Market will only increase, urging stakeholders to invest in improving and expanding biobanking infrastructures and technologies to meet the burgeoning healthcare demands.

### **Technological Advancements in Sample Preservation**

Technological advancements are revolutionizing the sample preservation techniques in the Human Biobanking Ownership Market Industry. Innovations such as automated sample handling equipment, advanced cryopreservation methods, and novel storage solutions have improved the preservation of biological materials, ensuring their viability over longer periods. These enhancements not only facilitate better quality control but also make biobanking more efficient and sustainable.

With the integration of sophisticated laboratory information management systems (LIMS), biobanks can now manage extensive datasets and maintain the integrity of samples with minimal human intervention. This capability is essential as the volume of biological samples increases, pushing for more efficient storage and retrieval mechanisms. Furthermore, advancements in data analytics allow for improved tracking and management of biobank resources, enabling researchers to access samples swiftly.

As technology progresses, it opens new avenues for processing and utilizing biobanked samples, leading to increased research opportunities and, ultimately, market growth.

### **Rising Investment in Biomedical Research**

The Human Biobanking Ownership Market Industry is benefitting from rising investments in biomedical research. Governments, private sectors and philanthropic organizations are increasingly funding research initiatives aimed at understanding complex diseases. This surge in funding is directly impacting the demand for biobanker samples whose availability is critical for genetic studies, drug development, and vaccine formulation. As research organizations expand their studies to include larger and more diverse biological samples, biobanks are playing a crucial role in supplying these resources.

Furthermore, the collaborative nature of biomedical research today promotes partnerships between academic institutions and biobanks, making it easier for researchers to access necessary samples. The growing recognition of the importance of biobanks in fostering innovation and discovery solidifies their role in the biomedical landscape, contributing to the market's growth potential.

## **Human Biobanking Ownership Market Segment Insights**

### **Human Biobanking Ownership Market Application Insights**

The Human Biobanking Ownership Market is seeing notable growth in its Application segment, which encompasses various fields essential to healthcare developments. In 2023, the segment is expected to generate significant revenue, representing a substantial part of the overall market evaluation. Among the key areas, Research stands out as the dominant segment, valued at 10.0 USD Billion, projected to grow to 16.0 USD Billion by 2032.

This area is vital for the advancement of therapeutic discoveries and scientific knowledge, making it a critical driver of biobanking activities. Clinical Trials, with a valuation of 8.0 USD Billion in 2023 and forecasted to reach 12.0 USD Billion by 2032, play a pivotal role in assessing the efficacy and safety of new treatments, thus contributing significantly to medical advancements. Personalized Medicine, valued at 6.0 USD Billion in 2023, projected to increase to 10.0 USD Billion by 2032, is gaining momentum as it tailors healthcare treatments to individual patient profiles, enhancing treatment outcomes and patient satisfaction.

Additionally, the Disease Prevention domain, starting at 4.95 USD Billion in 2023 and expected to expand to 7.0 USD Billion by 2032, focuses on the proactive management of health risks, ultimately aiding in reducing the incidence of diseases through careful monitoring and intervention. Each of these areas reflects the diverse applications of biobanking, highlighting the market's potential to enhance health outcomes and shape future healthcare practices.

The overall trends suggest that the Human Biobanking Ownership Market is on a path of continuous evolution, driven by emerging technologies, increasing research funding, and the growing need for personalized healthcare solutions. Together, these segments illustrate the market's expansive capabilities and underscore the ongoing investment and interest in biobanking as a fundamental asset in modern medicine.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Human Biobanking Ownership Market Type of Biobank Insights**

As the market evolves, the Type of Biobank segment plays a pivotal role, showcasing diverse categories, including Public Biobanks, Private Biobanks and Commercial Biobanks. Public Biobanks are fundamental for population health research and are often government or nonprofit-funded, allowing widespread access to biological samples. Meanwhile, Private Biobanks cater more to individual needs and are commonly associated with personal health management and specific research purposes.

Commercial Biobanks, on the other hand, generally focus on profit-driven models, offering services that cater to pharmaceutical companies and researchers seeking scalable solutions. With the increasing awareness of the importance of biobanks in biomedical research, the demand for these facilities continues to grow, driven by advancements in personalized medicine and genetic research. However, challenges such as ethical concerns and regulatory compliance remain pertinent within the industry.

Overall, the segmentation of the Human Biobanking Ownership Market into different types of biobanks highlights the robust landscape and informs stakeholders about potential opportunities for growth, as well as the importance of collaboration across various sectors.

### **Human Biobanking Ownership Market Sample Type Insights**

The Human Biobanking Ownership Market is continually evolving, with a significant focus on the Sample Type sector, which encompasses essential categories such as Blood Samples, Tissue Samples, Cell Lines and Biological Fluids. Blood Samples are of utmost importance due to their direct applications in numerous research and clinical scenarios, providing valuable insights into various diseases. Tissue Samples play a critical role in understanding cellular mechanisms and disease pathology, while Cell Lines are instrumental for drug development and therapeutic studies, often dominating research due to their versatility and longevity.

Biological Fluids, including saliva and urine, offer non-invasive means for biomarker analysis, presenting unique opportunities for patient monitoring and disease detection. The diversity in these sample types underscores the Human Biobanking Ownership Market segmentation, catering to growing demand across research, diagnostics and therapeutics. As this market progresses, it experiences trends fueled by technological advancements, increasing research funding, and rising awareness of precision medicine, driving sustained growth across all segments and making it an integral part of the health sciences landscape.

### **Human Biobanking Ownership Market End Use Insights**

The Human Biobanking Ownership Market is evolving, with a notable emphasis on end-use applications such as pharmaceutical companies, academic institutions and healthcare providers. Pharmaceutical companies play a pivotal role, as they rely significantly on human biobanks for drug development, personalized medicine, and clinical trials, thereby holding a major share of the market. Academic institutions also contribute substantially, harnessing biobank samples for research in human health, disease mechanisms, and innovative therapies, thus fostering academic collaboration and discovery.

Meanwhile, healthcare providers utilize biobanking to enhance diagnostic capabilities and improve patient-oriented care, driven by a focus on precision medicine initiatives. The growth in this segment is fueled by technological advancements, regulatory support, and rising public awareness regarding biobanking practices, but it faces challenges such as ethical concerns and regulatory complexities. Overall, the Human Biobanking Ownership Market segmentation indicates a diversified and growth-oriented industry with significant opportunities for further expansion.

### **Human Biobanking Ownership Market Regional Insights**

The Human Biobanking Ownership Market is poised for significant growth across various regions. In 2023, North America leads with a market valuation of 12.5 USD Billion, showing a substantial demand for biobanking services, driven by advanced research facilities and investments in healthcare. Europe follows closely with a valuation of 8.5 USD Billion, indicating a strong emphasis on research initiatives and stringent regulations promoting ethical practices in biobanking. The APAC region, valued at 5.5 USD Billion, is experiencing rapid growth due to increasing investments in healthcare infrastructure and rising awareness about biobanking.

South America and MEA, valued at 1.5 USD Billion and 0.9 USD Billion, respectively, represent emerging markets with potential for development, albeit at a smaller scale. The market dynamics indicate that North America and Europe dominate the landscape, driven by innovation and research advancements, while APAC shows a significant growth trajectory fueled by regional healthcare initiatives. With the increasing focus on personalized medicine and research collaborations globally, the demand for biobanks is expected to enhance market growth in upcoming years, making regional segmentation vital for understanding trends and opportunities within the Human Biobanking Ownership Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Human Biobanking Ownership Market Key Players and Competitive Insights**

The Human Biobanking Ownership Market is an expanding sector that serves as a critical facilitator for biomedical research and development by providing access to biological specimens. As the market evolves, competition intensifies among various organizations and institutions that seek to establish a solid presence in biobanking. Competitive insights reveal the importance of strategic partnerships, research collaborations, and technological advancements in enhancing the efficiency and effectiveness of biobanking processes.

Moreover, regulatory compliance and ethical considerations are essential factors that influence the operational dynamics within this market. Organizations aim to optimize their biobanking practices to ensure that they meet both scientific needs and regulatory requirements while maximizing the value derived from the samples they collect and maintain. Stanford University stands out in the Human Biobanking Ownership Market due to its strong emphasis on research innovation and interdisciplinary collaboration.

The institution has established a robust framework for biobanking that leverages its research capabilities across various fields, including genomics and personalized medicine. By integrating cutting-edge techniques and technologies, Stanford University enhances the capacity and quality of its biobanking resources. Furthermore, the university's ability to attract top-tier researchers contributes to a rich environment for scientific discovery and the development of novel therapeutic approaches. Stanford University also fosters significant collaborations with industry players and other academic institutions, solidifying its presence as a leader in the human biobanking landscape.

Bristol Myers Squibb has made a significant impact within the Human Biobanking Ownership Market through its commitment to advancing therapeutic research and development. The company recognizes the vital role that biobanks play in understanding diseases and developing new treatments, thereby enhancing patient outcomes. With a strategic focus on precision medicine and biomarker identification, Bristol Myers Squibb has invested in state-of-the-art biobanking solutions that align with its research priorities. The organization actively engages in partnerships that facilitate access to diverse biological samples, enhancing its data analysis capabilities and accelerating the drug development process.

Bristol Myers Squibb's reputation for innovation, along with its extensive experience in clinical trials, positions the company as a formidable player in the biobanking sector, underscoring its commitment to improving healthcare through scientific advancements.

### **Key Companies in the Human Biobanking Ownership Market Include**

## **Human Biobanking Ownership Market Industry Developments**

Recent developments in the Human Biobanking Ownership Market have highlighted significant activity among key players such as Stanford University, Bristol Myers Squibb, Illumina and Thermo Fisher Scientific. These entities continue to focus on enhancing biobanking infrastructures to support advanced research and personalized medicine. The market has seen an increase in collaborations and partnerships aimed at improving biobanking capabilities, ensuring greater access to diverse biological samples, and bolstering regulatory compliance.

Amidst these advancements, notable mergers and acquisitions have occurred. For instance, AstraZeneca's strategic partnership with GSK has strengthened their position in the biobanking sector, emphasizing its role in drug development and genomic research. Additionally, Genentech's acquisition of a biobank specializing in rare diseases showcases the growing importance of biobanks in targeted therapeutics. Market valuations have witnessed upward trends, with companies like Charles River Laboratories and Merck KGaA experiencing growth as demand for biobanking services increases.

This growth is driven by the rising need for customized healthcare solutions and advancements in genomic technologies, further propelling the market's potential. As investors recognize these trends, the competitive landscape within the Human Biobanking Ownership Market is evolving rapidly.

## **Human Biobanking Ownership Market Segmentation Insights**

### **Human Biobanking Ownership Market Application Outlook**

### **Human Biobanking Ownership Market Type of Biobank Outlook**

### **Human Biobanking Ownership Market Sample Type Outlook**

### **Human Biobanking Ownership Market End Use Outlook**

### **Human Biobanking Ownership Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Regulatory Support and Frameworks

人类生物银行所有权市场受益于支持性监管框架的建立，这些框架促进了伦理生物银行实践。各国政府和监管机构越来越认识到生物银行在推动医学研究中的重要性，同时确保捐赠者权利的保护。旨在标准化生物银行实践和增强透明度的举措正在实施，这可能会导致公众对生物银行的信任度提高。例如，知情同意和数据隐私指南的引入可能会鼓励更多个人捐赠生物样本。这种监管支持可能通过促进更强大和伦理的生物银行环境而潜在地扩大人类生物银行所有权市场。

### Rising Demand for Personalized Medicine

人类生物银行所有权市场正在经历个性化医学需求的显著激增。这一趋势是由基因组学和生物技术的进步推动的，这些进步使得根据个体基因特征制定量身定制的治疗方案成为可能。随着医疗提供者越来越多地采用精准医学方法，存储多样生物样本的生物银行的需求变得至关重要。根据最近的估计，个性化医学市场预计到2030年将达到2万亿美元，这为生物银行满足这一不断增长的领域提供了可观的机会。能够访问各种样本增强了研究能力，从而促进了药物开发和治疗策略的创新。因此，随着利益相关者认识到生物银行在支持个性化医疗倡议中的价值，人类生物银行所有权市场可能会扩大。

### Advancements in Research and Development

人类生物银行所有权市场受到各个领域（包括制药、生物技术和临床研究）持续研究与开发进展的显著影响。疾病的日益复杂性需要收集和分析多样的生物样本，以更好地理解疾病机制。随着研究机构和制药公司在研发上大量投资，对生物银行服务的需求预计将上升。报告显示，仅制药行业的全球研发支出在2023年就达到了约2000亿美元，突显了生物银行在促进创新研究中的关键作用。这一趋势表明，人类生物银行所有权市场将继续蓬勃发展，因为它为前沿科学研究提供了必要的资源。

### Growing Public Awareness and Participation

人类生物银行所有权市场正在见证公众对生物银行在推动医学研究中的重要性认识的提高。随着个人对生物银行在开发新治疗方法和理解疾病中的作用了解得越来越多，生物银行倡议的参与率也相应增加。教育宣传活动和外展项目有效地传达了生物银行的好处，这可能会导致可用于研究的生物样本池的扩大。这一趋势表明，随着更多个人选择贡献他们的样本，人类生物银行所有权市场可能会经历增长，从而增强生物银行的多样性和丰富性。

### Integration of Artificial Intelligence and Big Data

人类生物银行所有权市场通过整合人工智能（AI）和大数据分析正处于转型的边缘。这些技术使研究人员能够高效地分析大量生物数据，从而获得更准确的见解和发现。处理和解释复杂数据集的能力增强了生物银行的价值，使其在现代研究中不可或缺。随着人工智能的不断发展，其在生物银行中的应用可能会扩大，促进更好的样本管理和数据利用。预计到2025年，医疗保健领域的人工智能市场将达到360亿美元，这为人类生物银行所有权市场利用这些进展以改善研究成果提供了重要机会。

## Future Outlook

人类生物样本库所有权市场预计在2025年至2035年间以5.02%的年均增长率增长，推动因素包括技术进步、研究资金增加和个性化医学需求上升。

**New opportunities:**

- 开发先进的生物银行软件解决方案以进行数据管理。

到2035年，市场预计将强劲，反映出显著的增长和创新。

## Segment Insights

### 按应用：研究（最大）与个性化医学（增长最快）

在人类生物银行所有权市场中，应用细分主要分为研究、临床试验、个性化医学和疾病预防。在这些应用中，研究目前占据最大的市场份额，主要是由于对生物样本在科学研究和进步中的需求不断增加。紧随其后的是临床试验，利用生物银行样本测试新疗法，而个性化医学由于对量身定制的医疗解决方案的需求而迅速崛起，导致资源配置向这些应用的转移。

研究（主导）与个性化医学（新兴）

研究是人类生物银行所有权市场的主导力量，源于大量资金和需要生物样本进行验证的强大项目管道。它涵盖了各种科学研究，包括基因组学、蛋白质组学和药物开发，确保对生物银行服务的稳定需求。相反，个性化医学正在迅速崛起，受到技术进步和对量身定制疗法日益关注的推动。该应用利用生物银行样本识别遗传变异并开发个性化治疗方案，满足独特患者需求并改善治疗结果。

### 按生物银行类型：公共生物银行（最大）与私人生物银行（增长最快）

在人类生物银行所有权市场中，公共生物银行占据最大的份额，因其可及性和政府支持而代表了市场的一个重要部分。该细分专注于为研究和公共卫生倡议提供资源，获得学术机构和非营利组织的支持。与此同时，私人生物银行为个人和企业客户提供服务，随着个性化医学和基因检测的日益普及，正在迅速增长。

公共生物银行（主导）与私人生物银行（新兴）

公共生物银行在生物银行所有权市场中占据主导地位，拥有广泛的生物样本库，这些样本用于各种研究目的。这些生物银行通常面临较少的监管负担，并受益于更大的公众信任。相反，私人生物银行正在迅速崛起，受到消费者对个性化医疗解决方案日益关注的推动。这些生物银行通常专注于小众市场，提供一系列服务，从而促进其增长。这两个细分市场之间的竞争创造了一个动态的市场格局，双方都影响着生物银行材料在研究中的可用性和使用。

### 按样本类型：血液样本（最大）与组织样本（增长最快）

在人类生物银行所有权市场中，血液样本在该细分中占据主导地位，拥有相当大的市场份额，作为各种研究和临床应用的主要来源。虽然组织样本目前的份额较小，但由于生物银行技术的进步和对个性化医学需求的增加，正在迅速获得关注。它们提供对疾病和治疗反应的独特见解，使其成为研究领域的重要资产。

血液样本（主导）与组织样本（新兴）

血液样本是人类生物银行所有权市场的基石，广泛用于支持各种研究，包括基因组学、蛋白质组学和临床试验。它们的既定收集协议和广泛的现有样本库促进了它们的主导地位。相比之下，组织样本由于能够提供对细胞环境和疾病机制的详细见解，正在成为血液样本的重要补充。对转化研究和生物标志物发现的日益重视正在将组织样本推向聚光灯下，突显其在不断发展的生物银行领域中的相关性。

### 按最终用途：制药公司（最大）与学术机构（增长最快）

人类生物银行所有权市场受到三大主要最终用户的显著影响：制药公司、学术机构和医疗提供者。在这些用户中，制药公司占据最大的份额，利用生物银行进行药物开发、临床试验和个性化医学。然而，学术机构正在迅速获得关注，因为它们越来越专注于基因研究、公共卫生研究和开创性创新。相比之下，医疗提供者虽然在组织和样本采购中至关重要，但相对而言占据较小的市场份额，主要将生物银行用于常规诊断和患者护理。

制药公司（主导）与学术机构（新兴）

制药公司在生物银行所有权市场中处于前沿，利用生物银行获取对研究和药物开发至关重要的多样化生物样本。它们的主导地位得益于对生物银行技术的重大投资和与各种研究机构的合作。另一方面，学术机构正在成为这一领域的关键参与者，专注于利用生物银行推动科学知识的进步和促进学术研究。这一新趋势展示了它们在不仅为创新研究做出贡献，还吸引资金和合作方面的关键作用，从而增强了它们在市场中的地位。

## Regional Market Share Analysis

### 北美：引领创新与研究

北美是人类生物银行所有权的最大市场，占全球市场份额的约45%。该地区受益于先进的医疗基础设施、对研究和开发的重大投资，以及鼓励生物银行倡议的强大监管框架。对个性化医学和基因组研究日益增长的需求进一步推动了市场增长，得到了政府资金和旨在增强生物银行能力的倡议的支持。美国是该领域的领先国家，拥有生物库和克利夫兰诊所生物银行等主要参与者。加拿大也发挥着重要作用，越来越多的生物银行专注于多样化人群。竞争格局的特点是学术机构与私营实体之间的合作，促进创新并扩展该地区的生物银行服务。

### 欧洲：监管框架与增长

欧洲是人类生物银行所有权的第二大市场，占全球市场份额的约30%。该地区的增长受到严格法规的推动，这些法规确保生物银行中的伦理实践，同时公众对生物银行在医学研究中重要性的认识不断提高。欧盟推动生物银行和生物库的倡议进一步催化市场扩展，重点是协调成员国之间的法规。欧洲的主要国家包括英国、德国和芬兰，NHS血液与移植和生物银行等组织在其中占据重要地位。竞争格局的特点是公共和私营生物银行的混合，合作增强了研究能力。先进研究机构的存在以及对数据保护和患者同意的强烈重视在塑造市场动态中至关重要。

### 亚太地区：快速增长的市场潜力

亚太地区的人类生物银行所有权市场正在迅速增长，占全球市场份额的约20%。该地区的扩展受到对医疗基础设施的投资增加、对生物银行益处的认识提高以及旨在增强研究能力的政府倡议的推动。澳大利亚和日本等国正在引领这一进程，拥有鼓励生物银行实践和研究合作的支持性监管环境。澳大利亚以其建立的生物银行（如澳大利亚生物银行）而脱颖而出，而日本则专注于将生物银行整合到其医疗系统中。竞争格局正在演变，公共和私营实体都在进入市场。对个性化医学和基因组研究的重视正在推动对生物银行服务的需求，使亚太地区成为全球市场的关键参与者。

### 中东和非洲：面临挑战的新兴市场

中东和非洲地区是人类生物银行所有权的新兴市场，占全球市场份额的约5%。增长受到医疗投资增加、对研究的关注上升以及建立生物银行以支持当地医疗需求的推动。然而，监管障碍和公众意识有限等挑战阻碍了市场的更快发展。各国政府开始认识到生物银行在推动医疗和研究倡议中的重要性。南非和阿联酋等国正在积极努力建立生物银行，旨在改善医疗结果。竞争格局仍在发展，公共和私营实体正在探索生物银行的机会。政府与研究机构之间的合作努力对于克服现有挑战和增强该地区的生物银行能力至关重要。

## Competitive Benchmarking

人类生物银行所有权市场的特点是动态竞争格局，受到对生物样本在研究和临床应用中需求增加的推动。主要参与者积极参与强调创新、合作和区域扩展的战略，以增强其市场存在。例如，生物库（美国）专注于通过与学术机构的战略合作伙伴关系扩大其运营能力，从而增强其研究能力和样本多样性。同样，NHS血液与移植（英国）一直在投资数字化转型计划，以简化其生物银行流程，这使其在一个越来越重视效率和数据可获取性的市场中处于有利地位。市场结构似乎适度分散，多个参与者争夺主导地位。公司正在采用各种商业策略，例如本地化其运营以更好地服务区域市场，并优化供应链以降低成本。这种竞争结构允许提供多样化的产品，以满足特定的研究需求，从而增强生物银行服务的整体价值主张。
在8月，克利夫兰诊所生物银行（美国）宣布与一家领先的制药公司达成重要合作，以开发个性化医学解决方案。预计这一合作将利用生物银行的广泛遗传和临床数据，从而增强靶向疗法的开发。这种战略联盟不仅增强了生物银行的研究能力，还使其在不断发展的精准医学领域中成为关键参与者。
在9月，全球生物银行（英国）推出了一项新倡议，旨在通过教育项目和外展活动增加公众对生物银行的参与。这一举措在战略上非常重要，因为它试图为公众解开生物银行的神秘面纱，可能提高生物银行倡议的参与率。通过促进对生物银行益处的更好理解，全球生物银行旨在增强其样本收集工作并加强其社区联系。
在7月，组织解决方案（英国）将其业务扩展到亚太地区，在新加坡建立了新设施。这一扩展表明该公司计划进入需求上升的生物银行服务的新兴市场。通过本地化其运营，组织解决方案可以更好地满足区域研究需求，并增强其在全球市场中的竞争优势。
截至10月，人类生物银行所有权市场正在见证强调数字化、可持续性和人工智能整合的趋势。战略联盟越来越多地塑造竞争格局，使公司能够汇聚资源和专业知识。展望未来，竞争差异化可能会演变，从传统的基于价格的竞争转向关注创新、技术进步和供应链的可靠性。这一演变表明，优先考虑这些方面的公司将在未来更具竞争力。

## Recent News & Developments

在人类生物银行所有权市场的最新发展中，斯坦福大学、百时美施贵宝、Illumina和赛默飞世尔科技等主要参与者之间的活动显著增加。这些实体继续专注于增强生物银行基础设施，以支持先进的研究和个性化医学。市场上出现了旨在改善生物银行能力、确保更大访问多样生物样本和增强合规性的合作与伙伴关系。

在这些进展中，发生了显著的并购。例如，阿斯利康与GSK的战略合作加强了他们在生物银行领域的地位，强调其在药物开发和基因组研究中的作用。此外，基因泰克收购了一家专注于罕见疾病的生物银行，展示了生物银行在靶向治疗中的日益重要性。市场估值出现上升趋势，像查尔斯河实验室和默克KGaA等公司在生物银行服务需求增加的背景下实现了增长。

这种增长是由于对定制医疗解决方案的需求上升和基因组技术的进步，进一步推动了市场的潜力。随着投资者认识到这些趋势，人类生物银行所有权市场的竞争格局正在迅速演变。

## Report Scope

| 2024年市场规模 | 319.4（亿美元） |
| --- | --- |
| 2025年市场规模 | 335.4（亿美元） |
| 2035年市场规模 | 547.5（亿美元） |
| 年均复合增长率（CAGR） | 5.02%（2025 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 亿美元 |
| 主要公司简介 | 生物库（美国），全球生物银行（英国），组织解决方案（英国），克利夫兰诊所生物银行（美国），NHS血液与移植（英国），癌症研究（德国），生物银行（芬兰），澳大利亚生物银行（澳大利亚） |
| 覆盖的细分市场 | 应用、类型、生物库、样本类型、最终用途、区域 |
| 主要市场机会 | 个性化医学的出现推动了对多样化人类生物银行所有权解决方案的需求。 |
| 主要市场动态 | 日益严格的监管审查和技术进步正在重塑人类生物银行市场的所有权动态。 |
| 覆盖的国家 | 北美、欧洲、亚太地区、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 人类生物银行所有权市场的当前估值是多少？**
A: 市场估值在2024年为319.4亿美元。

**Q: 到2035年，人类生物银行所有权市场的预计市场规模是多少？**
A: 2035年的预计估值为547.5亿美元。

**Q: 在预测期内，人类生物银行所有权市场的预期年均增长率是多少？**
A: 2025年至2035年期间，市场的预期年均增长率为5.02%。

**Q: 哪些细分市场推动了人类生物银行所有权市场的增长？**
A: 主要细分市场包括研究、临床试验、个性化医学和疾病预防。

**Q: 到2035年，研究细分市场的预计估值是多少？**
A: 研究细分市场预计将从100亿美元增长到170亿美元。

**Q: 公共生物银行和私人生物银行在市场估值方面有何比较？**
A: 公共生物银行预计在100亿美元到170亿美元之间，而私人生物银行预计将从120亿美元增长到200亿美元。

**Q: 生物银行中最常用的样本类型有哪些？**
A: 血液样本、组织样本、细胞系和生物液体是主要的样本类型。

**Q: 制药公司在生物银行领域的市场表现预期如何？**
A: 制药公司预计在2035年市场范围为120亿美元到200亿美元。

**Q: 人类生物银行所有权市场的关键参与者是谁？**
A: 关键参与者包括生物库、全球生物银行、组织解决方案和克利夫兰诊所生物银行。

**Q: 个性化医学在人类生物银行所有权市场中的重要性是什么？**
A: 个性化医学细分市场预计将从70亿美元增长到110亿美元，表明其日益相关。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/human-biobanking-ownership-market-37911*